The genetics underlying acquired long QT syndrome: impact for genetic screening.

AIMS Acquired long QT syndrome (aLQTS) exhibits QT prolongation and Torsades de Pointes ventricular tachycardia triggered by drugs, hypokalaemia, or bradycardia. Sometimes, QTc remains prolonged despite elimination of triggers, suggesting the presence of an underlying genetic substrate. In aLQTS subjects, we assessed the prevalence of mutations in major LQTS genes and their probability of being carriers of a disease-causing genetic variant based on clinical factors. METHODS AND RESULTS We screened for the five major LQTS genes among 188 aLQTS probands (55 ± 20 years, 140 females) from Japan, France, and Italy. Based on control QTc (without triggers), subjects were designated 'true aLQTS' (QTc within normal limits) or 'unmasked cLQTS' (all others) and compared for QTc and genetics with 2379 members of 1010 genotyped congenital long QT syndrome (cLQTS) families. Cardiac symptoms were present in 86% of aLQTS subjects. Control QTc of aLQTS was 453 ± 39 ms, shorter than in cLQTS (478 ± 46 ms, P < 0.001) and longer than in non-carriers (406 ± 26 ms, P < 0.001). In 53 (28%) aLQTS subjects, 47 disease-causing mutations were identified. Compared with cLQTS, in 'true aLQTS', KCNQ1 mutations were much less frequent than KCNH2 (20% [95% CI 7-41%] vs. 64% [95% CI 43-82%], P < 0.01). A clinical score based on control QTc, age, and symptoms allowed identification of patients more likely to carry LQTS mutations. CONCLUSION A third of aLQTS patients carry cLQTS mutations, those on KCNH2 being more common. The probability of being a carrier of cLQTS disease-causing mutations can be predicted by simple clinical parameters, thus allowing possibly cost-effective genetic testing leading to cascade screening for identification of additional at-risk family members.

[1]  H. Rehm,et al.  Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.

[2]  M. Malik,et al.  Cardiac Safety Research Consortium: can the thorough QT/QTc study be replaced by early QT assessment in routine clinical pharmacology studies? Scientific update and a research proposal for a path forward. , 2014, American heart journal.

[3]  R. Altman,et al.  Genome Wide Analysis of Drug-Induced Torsades de Pointes: Lack of Common Variants with Large Effect Sizes , 2013, PloS one.

[4]  Michael J Ackerman,et al.  Impact of genetics on the clinical management of channelopathies. , 2013, Journal of the American College of Cardiology.

[5]  Michael J Ackerman,et al.  Phylogenetic and Physicochemical Analyses Enhance the Classification of Rare Nonsynonymous Single Nucleotide Variants in Type 1 and 2 Long-QT Syndrome , 2012, Circulation. Cardiovascular genetics.

[6]  Marylyn D. Ritchie,et al.  A Large Candidate Gene Survey Identifies the KCNE1 D85N Polymorphism as a Possible Modulator of Drug-Induced Torsades de Pointes , 2012, Circulation. Cardiovascular genetics.

[7]  E. Kaufman,et al.  Genotype-phenotype aspects of type 2 long QT syndrome. , 2009, Journal of the American College of Cardiology.

[8]  Michael J Ackerman,et al.  Genetic Testing for Long-QT Syndrome: Distinguishing Pathogenic Mutations From Benign Variants , 2009, Circulation.

[9]  P. Schwartz,et al.  NOS1AP Is a Genetic Modifier of the Long-QT Syndrome , 2009, Circulation.

[10]  M. Horie,et al.  Latent Genetic Backgrounds and Molecular Pathogenesis in Drug-Induced Long-QT Syndrome , 2009, Circulation. Arrhythmia and electrophysiology.

[11]  M. Horie,et al.  D85N, a KCNE1 polymorphism, is a disease-causing gene variant in long QT syndrome. , 2009, Journal of the American College of Cardiology.

[12]  D. Tester,et al.  Overrepresentation of the proarrhythmic, sudden death predisposing sodium channel polymorphism S1103Y in a population-based cohort of African-American sudden infant death syndrome. , 2008, Heart rhythm.

[13]  Beverley Balkau,et al.  Association of KCNQ1, KCNE1, KCNH2 and SCN5A polymorphisms with QTc interval length in a healthy population , 2005, European Journal of Human Genetics.

[14]  Dan M Roden,et al.  KCNH2-K897T Is a Genetic Modifier of Latent Congenital Long-QT Syndrome , 2005, Circulation.

[15]  P. C. Viswanathan,et al.  Genetics of acquired long QT syndrome. , 2005, The Journal of clinical investigation.

[16]  D. Tester,et al.  Compendium of cardiac channel mutations in 541 consecutive unrelated patients referred for long QT syndrome genetic testing. , 2005, Heart rhythm.

[17]  K. Hayashi,et al.  Probucol aggravates long QT syndrome associated with a novel missense mutation M124T in the N-terminus of HERG. , 2004, Clinical science.

[18]  Calum A MacRae,et al.  Risk stratification in the long-QT syndrome. , 2003, The New England journal of medicine.

[19]  M. Horie,et al.  Drug-Induced Long-QT Syndrome Associated With a Subclinical SCN5A Mutation , 2002, Circulation.

[20]  P. C. Viswanathan,et al.  Allelic Variants in Long-QT Disease Genes in Patients With Drug-Associated Torsades de Pointes , 2002, Circulation.

[21]  P. Coumel,et al.  C-terminal HERG mutations: the role of hypokalemia and a KCNQ1-associated mutation in cardiac event occurrence. , 1999, Circulation.

[22]  P. Coumel,et al.  KVLQT1 C-terminal missense mutation causes a forme fruste long-QT syndrome. , 1997, Circulation.

[23]  H. Bazett,et al.  AN ANALYSIS OF THE TIME‐RELATIONS OF ELECTROCARDIOGRAMS. , 1997 .

[24]  D. Wysowski,et al.  Cisapride and fatal arrhythmia. , 1996, The New England journal of medicine.

[25]  T. Kurita,et al.  Bradycardia-induced abnormal QT prolongation in patients with complete atrioventricular block with torsades de pointes. , 1992, The American journal of cardiology.

[26]  A. Moss,et al.  Delayed repolarization (QT or QTU prolongation) and malignant ventricular arrhythmias. , 1982, Modern concepts of cardiovascular disease.

[27]  R. Guy,et al.  International Conference on Harmonisation , 2014 .

[28]  International Conference on Harmonisation; guidance on E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs; availability. Notice. , 2005, Federal register.

[29]  Giuseppe Curigliano,et al.  Drug-induced prolongation of the QT interval. , 2004, The New England journal of medicine.